Petrányi G, Masszi T, Tímár L, Kriván G, Pálóczi K, Nagy K, Fekete S, Reményi P, Torbágyi E, Dénes R, Kelemen E
Országos Hematológiai és Immunológiai Intézet Csontvelóátültetó és Immunterápiás Osztály.
Orv Hetil. 1996 Oct 6;137(40):2203-8.
The article summarises the statistical data of bone marrow transplantation (BMT) carried out in Hungary between 1990-1995 in yearly distribution. Since the first BMT up to the end of 1995, 168 BMT were performed. The number of transplantations since 1990 to our days was gradually increasing. As a result of this activity in the three transplantation centers (National Institute of Haematology and Immunology, St. László Hospital and County Hospital in Miskolc) 36 allogeneic and 12 autologous BMT were performed in 1995. Out of the allogeneic BMT cases, 14% of them were completed with unrelated, donors in the last three years. The most frequent indications for allogenic BMT are: chronic myeloid leukaemia (CML), acute lymphoid leukaemia (ALL), acute myeloid leukaemia (AML), myelodysplasia, severe aplastic anaemia. Child allogenic BMTs are carried out on pediatric patients in St. László Hospital in leukaemia, severe aplastic anaemia cases and children born with immunodeficiency. Autologous BMTs started in an organised way in 1995 for adult patients in cases of non-Hodgkin lymphoma, Hodgkin lymphoma and for children with solid tumour indication in the Miskolc Centre. BMT activity in Hungary compared with international data, especially within Europe, shows a significant drop behind. To calculate for ten million inhabitants, the optimal BMT activity should be between 100-200 transplantations (allogeneic and autologous BMT together) in 1994. Among the Central European countries Hungary and Poland fall most behind. Autologous BMTs in most countries of Europe are above of allogeneic BMTs in numbers as indication in cases of lymphoma and solid tumours (first of all mamma carcinoma) comes into focus. This summary emphasises the most important difficulties in connection with the development of the National BMT program.
本文总结了1990年至1995年匈牙利每年进行骨髓移植（BMT）的统计数据。自首次进行BMT至1995年底，共进行了168例BMT。自1990年至今，移植数量逐渐增加。由于三个移植中心（国家血液学和免疫学研究所、圣拉兹洛医院以及米什科尔茨县医院）的此项工作，1995年进行了36例同种异体和12例自体BMT。在同种异体BMT病例中，过去三年有14%是由无关供体完成的。同种异体BMT最常见的适应症为：慢性粒细胞白血病（CML）、急性淋巴细胞白血病（ALL）、急性髓细胞白血病（AML）、骨髓发育异常、严重再生障碍性贫血。儿童同种异体BMT在圣拉兹洛医院针对白血病、严重再生障碍性贫血病例以及患有免疫缺陷的儿童患者进行。自体BMT于1995年开始有组织地在米什科尔茨中心为成年非霍奇金淋巴瘤、霍奇金淋巴瘤患者以及有实体瘤适应症的儿童患者开展。匈牙利的BMT活动与国际数据相比，尤其是在欧洲范围内，明显滞后。以每千万居民计算，1994年最佳BMT活动量应为100 - 200例移植（同种异体和自体BMT合计）。在中欧国家中，匈牙利和波兰最为滞后。在欧洲大多数国家，自体BMT的数量超过同种异体BMT，因为淋巴瘤和实体瘤（首先是乳腺癌）病例的适应症受到关注。本总结强调了与国家BMT项目发展相关的最重要困难。
